Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach.

UNLABELLED Copy number alterations (CNAs) are thought to account for 85% of the variation in gene expression observed among breast tumours. The expression of cis-associated genes is impacted by CNAs occurring at proximal loci of these genes, whereas the expression of trans-associated genes is impacted by CNAs occurring at distal loci. While a majority of these CNA-driven genes responsible for breast tumourigenesis are cis-associated, trans-associated genes are thought to further abet the development of cancer and influence disease outcomes in patients. Here we present a network-based approach that integrates copy-number and expression profiles to identify putative cis- and trans-associated genes in breast cancer pathogenesis. We validate these cis- and trans-associated genes by employing them to subtype a large cohort of breast tumours obtained from the METABRIC consortium, and demonstrate that these genes accurately reconstruct the ten subtypes of breast cancer. We observe that individual breast cancer subtypes are driven by distinct sets of cis- and trans-associated genes. Among the cis-associated genes, we recover several known drivers of breast cancer (e.g. CCND1, ERRB2, MDM2 and ZNF703) and some novel putative drivers (e.g. BRF2 and SF3B3). siRNA-mediated knockdown of BRF2 across a panel of breast cancer cell lines showed significant reduction in cell viability for ER-/HER2+ (MDA-MB-453) cells, but not in normal (MCF10A) cells thereby indicating that BRF2 could be a viable therapeutic target for estrogen receptor-negative/HER2-enriched (ER-/HER2+) cancers. Among the trans-associated genes, we identify modules of immune response (CD2, CD19, CD38 and CD79B), mitotic/cell-cycle kinases (e.g. AURKB, MELK, PLK1 and TTK), and DNA-damage response genes (e.g. RFC4 and FEN1). siRNA-mediated knockdown of RFC4 significantly reduced cell proliferation in ER-negative normal breast and cancer lines, thereby indicating that RFC4 is essential for both normal and cancer cell survival but could be a useful biomarker for aggressive (ER-negative) breast tumours. AVAILABILITY under NetStrat.

[1]  C. Yang,et al.  Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer , 2013, Cancer Gene Therapy.

[2]  Robert Gentleman,et al.  Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..

[3]  Ian M. Donaldson,et al.  iRefIndex: A consolidated protein interaction database with provenance , 2008, BMC Bioinformatics.

[4]  Calum MacAulay,et al.  Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma , 2010, PLoS medicine.

[5]  M. Cugmas,et al.  On comparing partitions , 2015 .

[6]  Adam B. Olshen,et al.  Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis , 2009, Bioinform..

[7]  Sriganesh Srihari,et al.  Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.

[8]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[9]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[10]  A. Hada,et al.  The knockdown of endogenous replication factor C4 decreases the growth and enhances the chemosensitivity of hepatocellular carcinoma cells , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[11]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[12]  Anne Vincent-Salomon,et al.  Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification , 2015, Genome Biology.

[13]  S. O'toole,et al.  Therapeutic targets in triple negative breast cancer , 2013, Journal of Clinical Pathology.

[14]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[15]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[17]  Kevin R Brown,et al.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.

[18]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[19]  Cheng Li,et al.  Lessons from a decade of integrating cancer copy number alterations with gene expression profiles , 2012, Briefings Bioinform..

[20]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[21]  Jerzy Majka,et al.  Requirement for ATP by the DNA Damage Checkpoint Clamp Loader* , 2004, Journal of Biological Chemistry.

[22]  Hon Wai Leong,et al.  Employing functional interactions for characterization and detection of sparse complexes from yeast PPI networks , 2012, Int. J. Bioinform. Res. Appl..

[23]  G. Chenevix-Trench,et al.  A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy , 2014, Nucleic acids research.

[24]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[25]  S. Janga,et al.  Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer , 2015, Modern Pathology.

[26]  Y. Huang,et al.  Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer , 2014, Journal of Translational Medicine.

[27]  Reuven Bar-Yehuda,et al.  A Linear-Time Approximation Algorithm for the Weighted Vertex Cover Problem , 1981, J. Algorithms.

[28]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Agnarsson,et al.  Chromosome 8p alterations in sporadic andBRCA2 999del5 linked breast cancer , 2000, Journal of medical genetics.

[30]  S. Brill,et al.  Rfc4 Interacts with Rpa1 and Is Required for Both DNA Replication and DNA Damage Checkpoints in Saccharomyces cerevisiae , 2001, Molecular and Cellular Biology.

[31]  Mark A. Ragan,et al.  Systematic tracking of dysregulated modules identifies novel genes in cancer , 2013, Bioinform..

[32]  Carlos Caldas,et al.  ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium , 2011, EMBO molecular medicine.

[33]  A. Gartel,et al.  Targeting FOXM1 in cancer. , 2013, Biochemical pharmacology.

[34]  B. Stillman,et al.  Biochemical Characterization of DNA Damage Checkpoint Complexes: Clamp Loader and Clamp Complexes with Specificity for 5′ Recessed DNA , 2003, PLoS biology.

[35]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[36]  Limsoon Wong,et al.  Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer , 2015, Biology Direct.

[37]  S. Lakhani,et al.  Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer , 2014, Oncogenesis.

[38]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[39]  FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. , 2012, Carcinogenesis.

[40]  S. Cabarcas,et al.  Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells , 2008, BMC Molecular Biology.

[41]  E. Lam,et al.  FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance , 2014, Biochimica et biophysica acta.

[42]  Howard Y. Chang,et al.  Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.

[43]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[45]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[46]  S. Cabarcas,et al.  RNA polymerase III transcription in cancer: the BRF2 connection , 2011, Molecular Cancer.

[47]  Chao Wang,et al.  iGPSe: A visual analytic system for integrative genomic based cancer patient stratification , 2014, BMC Bioinformatics.